David B. Kastrinsky, Ph.D. - Publications

Affiliations: 
2005 Scripps Research Institute, La Jolla, La Jolla, CA, United States 
Area:
synthetic organic chemistry

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 McClinch K, A Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, et al. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research. PMID 29358171 DOI: 10.1158/0008-5472.Can-17-0123  0.319
2017 Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The Journal of Clinical Investigation. PMID 28504649 DOI: 10.1172/Jci89548  0.326
2016 Sangodkar J, Tohme R, Kiselar J, Izadmehr S, Hoon D, Mazhar S, Perl A, Wiredja D, Schlatzer D, Yao S, Kastrinsky D, Sharma N, Brautigan D, Chance M, Borczuk A, et al. Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer Cancer Research. 76: 3865-3865. DOI: 10.1158/1538-7445.Am2016-3865  0.325
2015 Sangodkar J, Farrington C, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. The Febs Journal. PMID 26507691 DOI: 10.1111/Febs.13573  0.31
2015 Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M. Reengineered tricyclic anti-cancer agents. Bioorganic & Medicinal Chemistry. 23: 6528-34. PMID 26372073 DOI: 10.1016/J.Bmc.2015.07.007  0.314
2015 Sangodkar J, Izadmehr S, Mahzar S, Hoon D, Yao S, Kastrinsky D, Schlatzer D, Sharma N, Borczuk AC, Ohlmeyer M, Ioannou Y, Narla G. Abstract 5329: Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer Cancer Research. 75: 5329-5329. DOI: 10.1158/1538-7445.Am2015-5329  0.327
2015 McClinch K, Avelar R, Callejas D, Kastrinsky D, Ohlmeyer M, Plymate S, Galsky M, Narla G. Abstract C132: Therapeutic reactivation of PP2A for prostate cancer treatment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C132  0.302
2015 Sangodkar J, McQuaid D, Kisselar J, Brautigan D, Chance M, Ohlmeyer M, Kastrinsky D, Ioannou Y, Narla G. Abstract B124: Drugging the undruggable: development of small molecule activators of protein phosphatase 2A for cancer treatment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B124  0.349
2014 Sangodkar J, Mazhar S, Wiredja D, Gokulrangan G, Schlatzer D, Kastrinsky D, Difeo A, Yao S, Izadmehr S, Sharma N, Ioannou Y, Ohlmeyer M, Narla G. Abstract A38: Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor gene Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A38  0.345
2011 Dhawan N, Smith B, Sangodkar J, Gidwani V, Kastrinsky D, Ohlmeyer M, Narla G. Abstract A218: Simultaneous inhibition of both the PI3K-AKT and MAPK-ERK pathways using a single small molecule based approach for the treatment of advanced cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A218  0.35
2010 Robertson WM, Kastrinsky DB, Hwang I, Boger DL. Synthesis and evaluation of a series of C5'-substituted duocarmycin SA analogs. Bioorganic & Medicinal Chemistry Letters. 20: 2722-5. PMID 20381346 DOI: 10.1016/J.Bmcl.2010.03.078  0.553
2010 Kastrinsky DB, Barry CE. Synthesis of labeled meropenem for the analysis of M. tuberculosis transpeptidases. Tetrahedron Letters. 51: 197-200. PMID 20161438 DOI: 10.1016/J.Tetlet.2009.10.124  0.345
2006 Tichenor MS, Trzupek JD, Kastrinsky DB, Shiga F, Hwang I, Boger DL. Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer. Journal of the American Chemical Society. 128: 15683-96. PMID 17147378 DOI: 10.1021/Ja064228J  0.635
2004 Tichenor MS, Kastrinsky DB, Boger DL. Total synthesis, structure revision, and absolute configuration of (+)-yatakemycin. Journal of the American Chemical Society. 126: 8396-8. PMID 15237994 DOI: 10.1021/Ja0472735  0.524
2004 Kastrinsky DB, Boger DL. Effective asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI). The Journal of Organic Chemistry. 69: 2284-9. PMID 15049620 DOI: 10.1021/Jo035465X  0.489
2003 Parrish JP, Kastrinsky DB, Hwang I, Boger DL. Synthesis and evaluation of duocarmycin and CC-1065 analogues incorporating the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]-3-azaindol-4-one (CBA) alkylation subunit. The Journal of Organic Chemistry. 68: 8984-90. PMID 14604371 DOI: 10.1021/Jo035119F  0.562
2003 Parrish JP, Kastrinsky DB, Wolkenberg SE, Igarashi Y, Boger DL. DNA alkylation properties of yatakemycin. Journal of the American Chemical Society. 125: 10971-6. PMID 12952479 DOI: 10.1021/Ja035984H  0.635
2003 Parrish JP, Kastrinsky DB, Stauffer F, Hedrick MP, Hwang I, Boger DL. Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065. Bioorganic & Medicinal Chemistry. 11: 3815-38. PMID 12901927 DOI: 10.1016/S0968-0896(03)00194-9  0.551
2003 Parrish JP, Kastrinsky DB, Boger DL. Synthesis and X-ray analysis of an unprecedented and stable 2-aza-4,4-spirocyclopropacyclohexadienone. Organic Letters. 5: 2577-9. PMID 12841785 DOI: 10.1021/Ol035000T  0.497
Show low-probability matches.